RVMD

Revolution Medicines Inc

199.86

Sep 24 • 3:59 PM ET +9.12 (4.78%)

200.50

Aftermarket • 7:50 PM ET +0.64 (0.32%)

Healthcare Biotechnology USA Large NASD

Peers: ARGX REGN ONC VRTX ALNY BMRN BIIB AAPG AMGN GILD

| Held by: VTI VB VBK VXF IBB IWP IWR XBI IWF VHT

Index	-
Market Cap	42.84B
Enterprise Value	40.09B
Income	-1.77B
Sales	0.00M
Book/sh	12.16
Cash/sh	18.37
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	883
IPO	Feb 13, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	16.43
P/C	10.88
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	11.38
Current Ratio	11.38
Debt/Eq	0.46
LT Debt/Eq	0.45
Option/Short	Yes / Yes

EPS (ttm)	-8.81
EPS next Y	-6.02
EPS next Q	-2.40
EPS this Y	-62.73%
EPS next Y	37.81%
EPS next 5Y	22.27%
EPS past 3/5Y	-24.48% -29.13%
Sales past 3/5Y	- -
EPS Y/Y TTM	-95.67%
Sales Y/Y TTM	-100.00%
EPS Q/Q	-132.54%
Sales Q/Q	-
Earnings	Aug 05 AMC
EPS/Sales Surpr.	-49.81% -100.00%

Insider Own	9.95%
Insider Trans	-3.12%
Inst Own	92.45%
Inst Trans	6.44%
ROA	-52.37%
ROE	-79.09%
ROIC	-46.78%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-1.71%
SMA50	0.02%
SMA200	40.60%
Trades

Shs Outstand	214.24M
Shs Float	193.01M
Short Float	5.01%
Short Ratio	4.42
Short Interest	9.67M
52W High	224.31 -10.90%
52W Low	42.18 373.83%
Volatility	3.85% 4.08%
ATR (14)	7.69
RSI (14)	49.03
Beta	1.40
Rel Volume	1.86
Avg Volume	2.19M
Volume	4,066,872

Perf Week	1.48%
Perf Month	-5.45%
Perf Quarter	12.17%
Perf Half Y	111.96%
Perf YTD	150.92%
Perf Year	359.03%
Perf 3Y	566.20%
Perf 5Y	550.80%
Perf 10Y	-
Recom	1.09
Target Price	253.92
Prev Close	190.74
Price	199.86
Change %	4.78%

Date	Action	Analyst	Rating Change	Price Target Change
Today	Resumed	Goldman	Buy	$267
Sep-10-26	Initiated	Morgan Stanley	Overweight	$255
May-22-26	Initiated	Bernstein	Mkt Perform	$151
May-18-26	Resumed	Truist	Buy	$179
Mar-16-26	Resumed	Jefferies	Buy
Feb-27-26	Resumed	UBS	Buy	$145
Nov-18-25	Initiated	Wolfe Research	Outperform	$75
Nov-03-25	Initiated	RBC Capital Mkts	Outperform	$77
Oct-21-25	Initiated	Mizuho	Outperform	$90
Oct-16-25	Resumed	Stifel	Buy	$85
Sep-12-25	Resumed	Raymond James	Strong Buy	$72
Sep-05-25	Initiated	Truist	Buy	$99
Aug-19-25	Initiated	Piper Sandler	Overweight	$75
Aug-15-25	Initiated	Wells Fargo	Overweight	$67
Jul-15-25	Initiated	Goldman	Buy	$65
Jul-16-24	Reiterated	Needham	Buy	$46 → $62
Jul-12-24	Initiated	Barclays	Overweight	$52
Jul-08-24	Initiated	Jefferies	Buy	$63
Apr-12-24	Reiterated	Needham	Buy	$36 → $46
Apr-10-24	Upgrade	Raymond James	Outperform → Strong Buy	$36 → $48

Show Previous Ratings

Sep-14-26 04:05PM	Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer (GlobeNewswire)
Sep-10-26 01:14PM	'Miracle' Cancer Drug Sets Revolution Medicines Up for More Market Gains (Barrons.com)
Sep-04-26 05:00AM	Ionis rare neurology drug approved; Pfizer inks an ADC deal (BioPharma Dive)
Sep-02-26 05:50PM	New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines' RASONQUE (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer (GlobeNewswire)
Aug-28-26 10:13AM	New pancreatic cancer drug carries a $39,800 monthly list price: What to know (Yahoo Personal Finance) -6.00%
09:21PM	Loading…
Aug-27-26 09:21PM	Why the Drugmaker Behind a Pancreatic Cancer Breakthrough Stayed Independent (The Wall Street Journal)
02:54PM	Revolution Medicines $39,800-Monthly Cancer Drug Puts Access In Focus CEO Goldsmith Expects Insurers To Move Swiftly To Provide Coverage (Stocktwits)
07:37AM	3 Reasons the AI Stock Boom Is Very Much Back (Barrons.com)
Aug-26-26 06:33PM	Why Wall Street sees a $39,800 pancreatic cancer pill as proof of a much bigger bet (Fortune)
06:22PM	Sellas Traders See Pancreatic Cancer Race After RVMDs Drug Approval But Near-Term Focus Remains On SLSs Leukemia Pipeline (Stocktwits)
04:33PM	Bloomberg 500 (B500) Index Adds Ten Securities Following September Reconstitution (PR Newswire)
03:52PM	RVMD Stock Stays Flat Despite FDA Nod For $39,800-A-Month Pancreatic Cancer Pill Is Drug Price Overshadowing Approval? (Stocktwits)
12:59PM	U.S. FDA Approves Revolution Medicines' RASONQUE (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer (GlobeNewswire)
12:20PM	FDA Approves 'Unprecedented' Pancreatic Cancer Drug (Investor's Business Daily)
11:37AM	Revolution Medicines Wins FDA Approval for Pancreatic Cancer Pill. What It Means for the Stock. (Barrons.com)
09:35AM	Loading…
09:35AM	Revolution drug heralded as a pancreatic cancer breakthrough cleared by FDA (BioPharma Dive)
Aug-24-26 05:42AM	3 potential blockbusters beyond obesity to watch (Pharma Voice)
Aug-11-26 06:12AM	BeOne and Revolution Medicines partner for oncology therapies (Pharmaceutical Business Review)
Aug-10-26 06:00AM	BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration (Business Wire)
Aug-07-26 06:02AM	Significant demand for Revolution drug; Intellia pinpoints liver toxicity culprit (BioPharma Dive)
Aug-06-26 01:11AM	Revolution Medicines Inc (RVMD) (Q2 2026) Earnings Call Highlights: Daraxonrasib Poised to ... (GuruFocus.com)
Aug-05-26 04:02PM	Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress (GlobeNewswire)
Aug-03-26 12:45PM	Read Between These Lines As Eli Lilly, Hot IPO And More Face Key Test (Investor's Business Daily)
Jul-29-26 04:05PM	Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026 (GlobeNewswire) +6.22%
Jul-24-26 07:30AM	Big pharmas patent cliff meets a new biotech Cold War: We need to outrun China, not outlaw it (Fortune)
05:00AM	Novo escalates legal fight with Lilly; J&J reinforces dominance in multiple myeloma (BioPharma Dive)
Jul-22-26 04:05PM	Revolution Medicines' New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer (GlobeNewswire)
Jul-08-26 05:07AM	Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversal (BioPharma Dive)
Jul-07-26 09:23AM	European Medicines Agency Expedites Assessment of Revolution Medicines' Daraxonrasib Under Phased Review Process (GlobeNewswire)
Jul-03-26 07:20AM	Revolutions RAS inhibitor pipeline posts more pancreatic cancer trial wins (Clinical Trials Arena)
08:00AM	Loading…
Jul-02-26 08:00AM	Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026 (GlobeNewswire)
Jun-26-26 03:38PM	This Biotech ETF Has Almost Doubled in 13 Months. Money Is Flowing In. (Barrons.com)
07:53AM	FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services (BioPharma Dive)
Jun-24-26 07:31PM	Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026 (GlobeNewswire)
Jun-23-26 08:00AM	Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer (GlobeNewswire)
Jun-22-26 08:00AM	Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D. (GlobeNewswire)
Jun-09-26 09:32AM	Tango Therapeutics stock surges on pancreatic cancer drug combo data (Quartz)
09:31AM	Tango Therapeutics stock surges on pancreatic cancer trial data (Quartz)
Jun-08-26 04:09PM	Tango Skyrockets On Eye-Popping Pancreatic Cancer Results (Investor's Business Daily)
12:28PM	Tango Therapeutics Stock Soars 42% After 'Unprecedented' Data on Pancreatic Cancer Treatment (Barrons.com)
08:13AM	Tango data add to growing momentum for pancreatic cancer drugs (BioPharma Dive)
Jun-05-26 04:55AM	GSK, Takeda and others notch key clinical wins in tough-to-treat diseases (Pharma Voice)
Jun-01-26 10:26AM	Revolution Medicines Jumps 12% As Cancer Drug Data Strengthens Case (GuruFocus.com)
May-31-26 09:01PM	RVMD Stock Jumps Overnight: New Drug Heads To FDA After Unprecedented 1-Year Survival Win In Pancreatic Cancer (Stocktwits)
08:06AM	Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer (GlobeNewswire)
May-22-26 07:46AM	ASCO26: 5 data snapshots ahead of the years biggest cancer drug meeting (BioPharma Dive)
May-21-26 04:05PM	Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation (GlobeNewswire)
May-07-26 08:30AM	Revolution Medicines, Inc. Q1 2026 Earnings Call Summary (Moby) -5.67%
May-06-26 06:00PM	Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer (GlobeNewswire)
04:02PM	Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress (GlobeNewswire)
Apr-29-26 04:05PM	Revolution Medicines to Report Financial Results for First Quarter 2026 After Market Close on May 6, 2026 (GlobeNewswire)
03:07PM	Erasca Shares Plunge 48% After Trial Patient Death, Patent Dispute Emerges (GuruFocus.com)
03:50AM	Revolutions on a pancreatic cancer winning streak. What comes next for the biotech? (Pharma Voice)
Apr-28-26 03:58PM	Erasca Shares Crater After Cancer Trial Update Reveals Patient Death (The Wall Street Journal) +9.99%
09:33AM	Erasca Plummets Despite 'Phenomenal' Results In Pancreatic Cancer (Investor's Business Daily)
05:30AM	There's a Revolution in Cancer. But Can Big Pharma Afford It? (The Wall Street Journal)
Apr-21-26 05:35PM	Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting (GlobeNewswire)
05:30PM	Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting (GlobeNewswire)
11:23AM	Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting (GlobeNewswire)
Apr-20-26 06:43AM	AACR 2026: Revolutions next prospect, Mercks reveal and a lung cancer battle (BioPharma Dive)
Apr-19-26 02:00PM	Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting (GlobeNewswire)
Apr-17-26 04:02PM	Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Apr-16-26 07:00AM	Replimune cuts staff; MeiraGTx reacquires eye gene therapy (BioPharma Dive)
Apr-15-26 12:41AM	Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes (GlobeNewswire)
Apr-13-26 04:01PM	Revolution Medicines, Inc. Announces Proposed Offerings of Common Stock and Convertible Senior Notes (GlobeNewswire) +41.35% +7.86%
11:09AM	Revolution Medicines' potential breakthrough pancreatic cancer drug succeeds in late-stage trial (CNBC TV)
10:34AM	How This Biotech Stock Skirted Today's Selloff (Schaeffer's Research)
09:11AM	This Biotech Stock Soars 38%. Pancreatic Cancer Trial Was a Success. (Barrons.com)
09:11AM	Revolution Medicines Catapults 30%-Plus On Upbeat Results For Pancreatic Cancer Drug (Investor's Business Daily)
08:00AM	Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer (GlobeNewswire)
07:46AM	Revolution pancreatic cancer drug nearly doubles survival in key trial (BioPharma Dive)
Apr-10-26 05:57PM	Former Sen. Ben Sasse shines the spotlight on a possible breakthrough for pancreatic cancer (CNBC TV)
Apr-02-26 08:00AM	Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer (GlobeNewswire)
Mar-17-26 06:37PM	Revolution Medicines to Showcase Progress Across RAS(ON) Targeted Oncology Pipeline with Multiple Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Mar-05-26 04:10PM	Tango Therapeutics, Up 39% This Year, Surges Again On Another Cancer Pact (Investor's Business Daily)
Mar-02-26 02:57AM	Revolution Medicines, Inc. (RVMD) Net Loss Widens amid Progress on Clinical Trial Programs (Insider Monkey)
Feb-26-26 11:53PM	Evercore ISI Initiates Revolution Medicines (RVMD) With an Outperform Rating - Here's Why (Insider Monkey)
09:38AM	RVMD Reports Wider-Than-Expected Q4 Loss, Issues 2026 Expense View (Zacks)
08:30AM	Revolution Medicines, Inc. Q4 2025 Earnings Call Summary (Moby)
08:04AM	Has Revolution Medicines (RVMD) Found a Breakthrough in Cancer Treatment? (Insider Monkey)
02:11AM	Revolution Medicines Q4 Earnings Call Highlights (MarketBeat)
12:04AM	Revolution Medicines Inc (RVMD) Q4 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Feb-25-26 04:02PM	Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress (GlobeNewswire)
Feb-24-26 04:05PM	Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference (GlobeNewswire)
08:30AM	Summit Therapeutics Inc. Q4 2025 Earnings Call Summary (Moby)
01:23AM	JPMorgan Signals High Conviction Ahead of Revolution Medicines (RVMD) Readout (Insider Monkey)
Feb-18-26 04:05PM	Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026 (GlobeNewswire)
Feb-15-26 02:02PM	Tango Therapeutics CEO Teases Pivotal Vopimetostat Trial, RAS Combo Data at Guggenheim Chat (MarketBeat)
Feb-14-26 10:02PM	Revolution Medicines Conference: CEO Details Daraxonrasib Phase III Timeline, First-Line PDAC Push (MarketBeat)
Feb-13-26 02:07PM	Erasca Touts Early ERAS-0015 Responses, Potency Edge in Guggenheim Fireside Chat (MarketBeat)
Feb-04-26 04:05PM	Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Jan-29-26 08:00AM	Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor (GlobeNewswire)
Jan-27-26 10:53AM	RVMD Stock Tumbles as MRK Reportedly Withdraws Buyout Offer (Zacks)
06:23AM	Stock Index Futures Gain on Tech Boost, FOMC Meeting and Earnings in Focus (Barchart)
05:02AM	Revolution Medicines (RVMD) Dives 16.9% as Merck Withdraws Takeover Plan (Insider Monkey)
03:39AM	Stock Market Today: Nasdaq Futures Rise Ahead of Earnings; Yen Weakens (The Wall Street Journal)
Jan-26-26 07:36PM	Why Revolution Medicines Stock Plummeted by Almost 17% Today (Motley Fool) -16.87%
04:56PM	Stocks to Watch Monday Recap: CoreWeave, IonQ, USA Rare Earth, RevMed (The Wall Street Journal)
04:32PM	Stocks Close Higher Ahead of Heavy Earnings Week and FOMC Meeting (Barchart)
01:48PM	Stocks to Watch Monday: CoreWeave, IonQ, USA Rare Earth, RevMed (The Wall Street Journal)

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Ph.D.Dr. Mark A. Goldsmith M.D.

Chief Financial OfficerMr. Jack Anders

Chief Operating OfficerMs. Margaret A. Horn J.D.

Senior VPMr. Jeffrey Cislini J.D.

FRCPDr. Stephen M. Kelsey FRC Path.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ANDERSON ELIZABETH M	Director	Sep 22 '26	Option Exercise	1.12	5,070	5,678	14,476	Sep 24 06:00 PM
ANDERSON ELIZABETH M	Director	Sep 22 '26	Sale	193.04	10,143	1,958,016	4,333	Sep 24 06:00 PM
ANTHONY MANCINI	Officer	Sep 24 '26	Proposed Sale	190.74	587	111,964		Sep 24 04:42 PM
Mancini Anthony	See Remarks	Sep 18 '26	Sale	196.94	1,764	347,402	40,352	Sep 22 06:00 PM
Elizabeth Anderson	Director	Sep 22 '26	Proposed Sale	192.76	15,080	2,906,821		Sep 22 04:13 PM
Sandler Alan B.	Chief Development Officer	Sep 16 '26	Sale	199.24	341	67,941	52,868	Sep 18 06:06 PM
Mancini Anthony	See Remarks	Sep 16 '26	Sale	199.24	1,774	353,449	42,116	Sep 18 06:05 PM
Kelsey Stephen Michael	See Remarks	Sep 16 '26	Sale	199.24	5,569	1,109,554	286,307	Sep 18 06:04 PM
Horn Margaret A	Chief Operating Officer	Sep 16 '26	Sale	199.24	4,967	989,613	149,680	Sep 18 06:03 PM
GOLDSMITH MARK A	See Remarks	Sep 16 '26	Sale	199.24	13,988	2,786,938	253,342	Sep 18 06:02 PM
Cislini Jeff	SVP & General Counsel	Sep 16 '26	Sale	199.24	3,366	670,631	52,541	Sep 18 06:01 PM
Anders Jack	Chief Financial Officer	Sep 16 '26	Sale	199.24	4,053	807,513	119,216	Sep 18 06:00 PM
ANTHONY MANCINI	Officer	Sep 18 '26	Proposed Sale	196.94	1,764	347,402		Sep 18 04:18 PM
Sandler Alan B	Officer	Sep 15 '26	Proposed Sale	203.77	331	67,448		Sep 15 06:11 PM
Mancini Anthony	Officer	Sep 15 '26	Proposed Sale	203.77	2,377	484,361		Sep 15 06:10 PM
Kelsey Stephen Michael	Officer	Sep 15 '26	Proposed Sale	203.77	5,415	1,103,415		Sep 15 06:09 PM
Horn Margaret A	Officer	Sep 15 '26	Proposed Sale	203.77	4,830	984,209		Sep 15 06:08 PM
Goldsmith Mark A	Officer	Sep 15 '26	Proposed Sale	203.77	13,603	2,771,883		Sep 15 06:07 PM
Cislini Jeff	Officer	Sep 15 '26	Proposed Sale	203.77	3,272	666,735		Sep 15 06:06 PM
Anders Jack	Officer	Sep 15 '26	Proposed Sale	203.77	3,939	802,650		Sep 15 06:05 PM
Kelsey Stephen Michael	See Remarks	Sep 11 '26	Option Exercise	41.71	92,531	3,859,488	384,407	Sep 15 06:00 PM
Kelsey Stephen Michael	See Remarks	Sep 11 '26	Sale	202.36	92,531	18,724,767	291,876	Sep 15 06:00 PM
Mancini Anthony	See Remarks	Sep 10 '26	Option Exercise	33.62	9,363	314,784	59,338	Sep 14 06:03 PM
Mancini Anthony	See Remarks	Sep 10 '26	Sale	204.16	15,448	3,153,807	43,890	Sep 14 06:03 PM
STEPHEN KELSEY	Officer	Sep 11 '26	Proposed Sale	203.35	92,531	18,816,179		Sep 11 04:32 PM
Kim Lorence H.	Director	Sep 08 '26	Sale	209.82	17,090	3,585,837	0	Sep 10 05:52 PM
ANTHONY MANCINI	Officer	Sep 10 '26	Proposed Sale	207.68	15,448	3,208,241		Sep 10 04:39 PM
Kim Lorence H.	Director	Aug 31 '26	Sale	203.24	56,000	11,381,288	17,090	Sep 02 04:30 PM
Lorence H Kim	Affiliate	Aug 31 '26	Proposed Sale	207.88	73,090	15,193,949		Aug 31 05:11 PM
Cislini Jeff	General Counsel	Aug 21 '26	Option Exercise	20.00	56,280	1,125,687	112,801	Aug 25 04:06 PM
Cislini Jeff	General Counsel	Aug 21 '26	Sale	209.24	56,894	11,904,247	55,907	Aug 25 04:06 PM
GOLDSMITH MARK A	See Remarks	Aug 21 '26	Option Exercise	4.73	80,000	378,400	347,330	Aug 25 04:06 PM
GOLDSMITH MARK A	See Remarks	Aug 21 '26	Sale	209.20	80,000	16,735,887	267,330	Aug 25 04:06 PM
GOLDSMITH MARK A	See Remarks	Aug 21 '26	Sale	209.20	6,000	1,255,219	61,424	Aug 25 04:06 PM
THE JONATHAN GOLDSMITH REVOCAB	Director	Aug 21 '26	Proposed Sale	211.74	3,000	635,205		Aug 21 04:38 PM
THE REBECCA GOLDSMITH REVOCABL	Director	Aug 21 '26	Proposed Sale	211.74	3,000	635,205		Aug 21 04:38 PM
MARK A GOLDSMITH	Director	Aug 21 '26	Proposed Sale	211.74	80,000	16,938,800		Aug 21 04:37 PM
JEFFREY TODD CISLINI	Officer	Aug 21 '26	Proposed Sale	211.73	75,894	16,069,416		Aug 21 04:33 PM
Patel Sushil	Director	Jun 29 '26	Option Exercise	37.54	2,955	110,931	27,236	Jul 01 06:25 PM
Patel Sushil	Director	Jun 29 '26	Sale	187.99	5,580	1,048,967	21,656	Jul 01 06:25 PM
SUSHIL PATEL	Director	Jun 29 '26	Proposed Sale	182.08	5,580	1,016,006		Jun 29 04:44 PM
Anders Jack	Chief Financial Officer	Jun 24 '26	Option Exercise	18.56	20,000	371,200	143,269	Jun 26 04:10 PM
Anders Jack	Chief Financial Officer	Jun 24 '26	Sale	168.33	20,000	3,366,604	123,269	Jun 26 04:10 PM
JACK ANDERS	Officer	Jun 24 '26	Proposed Sale	169.51	20,000	3,390,200		Jun 24 04:35 PM
Mancini Anthony	See Remarks	Jun 16 '26	Sale	156.12	4,615	720,490	49,975	Jun 18 04:11 PM
GOLDSMITH MARK A	See Remarks	Jun 16 '26	Sale	156.12	10,020	1,564,310	267,330	Jun 18 04:11 PM
Cislini Jeff	General Counsel	Jun 16 '26	Sale	156.12	2,157	336,749	56,521	Jun 18 04:10 PM
Anders Jack	Chief Financial Officer	Jun 16 '26	Sale	156.12	2,722	424,956	123,269	Jun 18 04:10 PM
Kelsey Stephen Michael	See Remarks	Jun 16 '26	Sale	156.12	4,175	651,798	291,876	Jun 18 04:10 PM
Horn Margaret A	Chief Operating Officer	Jun 15 '26	Option Exercise	32.62	60,400	1,969,993	218,622	Jun 17 07:51 PM
Horn Margaret A	Chief Operating Officer	Jun 17 '26	Option Exercise	27.14	29,600	803,456	184,247	Jun 17 07:51 PM
Horn Margaret A	Chief Operating Officer	Jun 15 '26	Sale	160.17	60,400	9,674,304	158,222	Jun 17 07:51 PM
Horn Margaret A	Chief Operating Officer	Jun 17 '26	Sale	160.12	29,600	4,739,679	154,647	Jun 17 07:51 PM
GOLDSMITH MARK A	Officer	Jun 15 '26	Proposed Sale	153.87	9,772	1,503,618		Jun 15 06:30 PM
Cislini Jeff	Officer	Jun 15 '26	Proposed Sale	153.87	1,656	254,809		Jun 15 06:23 PM
Anders Jack	Officer	Jun 15 '26	Proposed Sale	153.87	2,653	408,217		Jun 15 06:15 PM
Mancini Anthony	Officer	Jun 15 '26	Proposed Sale	153.87	4,211	647,947		Jun 15 06:07 PM
Kelsey Stephen Michael	Officer	Jun 15 '26	Proposed Sale	153.87	4,071	626,405		Jun 15 05:59 PM
Horn Margaret A	Officer	Jun 15 '26	Proposed Sale	153.87	3,486	536,391		Jun 15 05:51 PM
MARGARET A HORN	Officer	Jun 15 '26	Proposed Sale	153.87	90,000	13,848,300		Jun 15 04:59 PM
Horn Margaret A	Chief Operating Officer	Jun 11 '26	Option Exercise	40.93	10,000	409,271	168,222	Jun 15 04:05 PM
Horn Margaret A	Chief Operating Officer	Jun 11 '26	Sale	148.01	10,000	1,480,139	158,222	Jun 15 04:05 PM
MARGARET A HORN	Officer	Jun 11 '26	Proposed Sale	144.19	10,000	1,441,900		Jun 11 04:28 PM
Mancini Anthony	See Remarks	May 26 '26	Option Exercise	33.62	3,121	104,928	57,521	May 28 04:10 PM
Mancini Anthony	See Remarks	May 26 '26	Sale	153.99	3,121	480,611	54,400	May 28 04:10 PM
ANTHONY MANCINI	Officer	May 26 '26	Proposed Sale	151.56	3,121	473,019		May 26 04:46 PM
Mancini Anthony	See Remarks	Apr 27 '26	Option Exercise	33.62	3,120	104,894	57,520	Apr 29 05:50 PM
Mancini Anthony	See Remarks	Apr 27 '26	Sale	132.41	3,120	413,129	54,400	Apr 29 05:50 PM
ANTHONY MANCINI	Officer	Apr 27 '26	Proposed Sale	135.30	3,120	422,136		Apr 27 04:32 PM
GOLDSMITH MARK A	See Remarks	Apr 15 '26	Option Exercise	4.61	120,000	552,724	396,698	Apr 17 07:26 PM
GOLDSMITH MARK A	See Remarks	Apr 15 '26	Sale	150.09	120,000	18,010,488	276,698	Apr 17 07:26 PM
MARK A GOLDSMITH	Director	Apr 15 '26	Proposed Sale	147.01	120,000	17,641,200		Apr 15 04:53 PM
Mancini Anthony	See Remarks	Mar 25 '26	Option Exercise	33.62	37,450	1,259,069	91,850	Mar 26 08:04 PM
Mancini Anthony	See Remarks	Mar 25 '26	Sale	95.56	37,450	3,578,821	54,400	Mar 26 08:04 PM
Mancini Anthony	Officer	Mar 25 '26	Proposed Sale	95.56	37,450	3,578,823		Mar 26 08:01 PM
Wei Lin	Chief Medical Officer	Mar 17 '26	Sale	99.48	2,073	206,223	101,366	Mar 19 06:57 PM
Kelsey Stephen Michael	See Remarks	Mar 17 '26	Sale	99.48	4,302	427,965	295,398	Mar 19 06:57 PM
GOLDSMITH MARK A	See Remarks	Mar 17 '26	Sale	99.48	12,871	1,280,412	276,698	Mar 19 06:56 PM
Horn Margaret A	Chief Operating Officer	Mar 17 '26	Sale	99.48	4,583	455,919	157,570	Mar 19 06:56 PM
Anders Jack	Chief Financial Officer	Mar 17 '26	Sale	99.48	2,753	273,870	125,512	Mar 19 06:55 PM
Cislini Jeff	General Counsel	Mar 17 '26	Sale	99.48	1,795	178,567	59,681	Mar 19 06:54 PM
Cislini Jeff	General Counsel	Mar 19 '26	Sale	97.44	1,163	113,323	58,518	Mar 19 06:54 PM
Wang Xiaolin	See Remarks	Mar 17 '26	Sale	99.48	2,010	199,956	116,063	Mar 19 06:53 PM
JEFFREY TODD CISLINI	Officer	Mar 19 '26	Proposed Sale	98.11	1,163	114,102		Mar 19 04:22 PM
Wang Xiaolin	Officer	Mar 16 '26	Proposed Sale	99.59	2,282	227,264		Mar 13 07:41 PM
Wei Lin	Officer	Mar 16 '26	Proposed Sale	99.59	2,288	227,862		Mar 13 07:40 PM
Kelsey Stephen Michael	Officer	Mar 16 '26	Proposed Sale	99.59	3,901	388,501		Mar 13 07:38 PM
Horn Margaret A	Officer	Mar 16 '26	Proposed Sale	99.59	4,722	470,264		Mar 13 07:36 PM
GOLDSMITH MARK A	Officer	Mar 16 '26	Proposed Sale	99.59	13,261	1,320,663		Mar 13 07:34 PM
Cislini Jeff	Officer	Mar 16 '26	Proposed Sale	99.59	2,053	204,458		Mar 13 07:31 PM
Anders Jack	Officer	Mar 16 '26	Proposed Sale	99.59	2,134	212,525		Mar 13 07:24 PM
GOLDSMITH MARK A	See Remarks	Mar 02 '26	Option Exercise	4.09	30,000	122,700	319,569	Mar 03 09:09 PM
GOLDSMITH MARK A	See Remarks	Mar 02 '26	Sale	101.22	30,000	3,036,576	289,569	Mar 03 09:09 PM
GOLDSMITH MARK A	See Remarks	Mar 02 '26	Sale	101.30	6,000	607,778	64,424	Mar 03 09:09 PM
JONATHAN GOLDSMITH REVOCABLE T	Director	Mar 02 '26	Proposed Sale	102.02	3,000	306,060		Mar 02 04:33 PM
THE REBECCA GOLDSMITH REVOCABL	Director	Mar 02 '26	Proposed Sale	102.02	3,000	306,060		Mar 02 04:33 PM
MARK A GOLDSMITH	Director	Mar 02 '26	Proposed Sale	102.02	30,000	3,060,600		Mar 02 04:32 PM
GOLDSMITH MARK A	See Remarks	Feb 06 '26	Option Exercise	0.54	24,010	12,965	256,479	Feb 10 05:30 PM
Cislini Jeff	General Counsel	Jan 21 '26	Sale	115.60	908	104,965	46,976	Jan 23 04:31 PM
JEFFREY TODD CISLINI	Officer	Jan 21 '26	Proposed Sale	116.22	908	105,528		Jan 21 04:23 PM

Open in Screener

INSM

Insmed Inc

121.55

Sep 24 • 3:59 PM ET +3.21 (2.71%)

121.30

Aftermarket • 7:45 PM ET -0.25 (-0.21%)

Healthcare Biotechnology USA Large NASD

Peers: BMRN ALNY ARGX REGN RVMD VRTX RPRX BIIB AMGN GILD

| Held by: VTI VXF VB VO VUG IBB VBK XBI IWP IWR

Index	-
Market Cap	26.54B
Enterprise Value	26.13B
Income	-875.31M
Sales	1.14B
Book/sh	3.47
Cash/sh	5.31
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	1664
IPO	Feb 15, 1991

P/E	-
Forward P/E	151.37
PEG	-
P/S	23.33
P/B	35.03
P/C	22.88
P/FCF	-
EV/EBITDA	-
EV/Sales	22.97
Quick Ratio	3.40
Current Ratio	3.72
Debt/Eq	0.99
LT Debt/Eq	0.96
Option/Short	Yes / Yes

EPS (ttm)	-4.11
EPS next Y	0.80
EPS next Q	-0.39
EPS this Y	75.12%
EPS next Y	150.28%
EPS next 5Y	-
EPS past 3/5Y	-17.91% -16.32%
Sales past 3/5Y	35.20% 29.83%
EPS Y/Y TTM	28.02%
Sales Y/Y TTM	185.76%
EPS Q/Q	96.42%
Sales Q/Q	296.11%
Earnings	Aug 06 BMO
EPS/Sales Surpr.	91.08% 7.58%

Insider Own	1.48%
Insider Trans	-15.96%
Inst Own	102.74%
Inst Trans	-0.64%
ROA	-38.20%
ROE	-87.22%
ROIC	-58.85%
Gross Margin	82.78%
Oper. Margin	-71.43%
Profit Margin	-76.94%
SMA20	-1.45%
SMA50	2.12%
SMA200	-10.30%
Trades

Shs Outstand	218.28M
Shs Float	215.15M
Short Float	5.02%
Short Ratio	4.17
Short Interest	10.80M
52W High	212.75 -42.87%
52W Low	90.39 34.47%
Volatility	3.53% 3.94%
ATR (14)	4.93
RSI (14)	49.01
Beta	0.82
Rel Volume	0.86
Avg Volume	2.59M
Volume	2,233,624

Perf Week	-1.96%
Perf Month	-1.89%
Perf Quarter	16.35%
Perf Half Y	-18.04%
Perf YTD	-30.16%
Perf Year	-13.79%
Perf 3Y	364.46%
Perf 5Y	350.02%
Perf 10Y	723.51%
Recom	1.12
Target Price	199.04
Prev Close	118.34
Price	121.55
Change %	2.71%

Date	Action	Analyst	Rating Change	Price Target Change
Today	Resumed	Goldman	Buy	$188
Jul-21-26	Initiated	BMO Capital Markets	Outperform	$192
Apr-10-26	Initiated	Raymond James	Outperform	$200
Mar-30-26	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$212
Mar-16-26	Resumed	Jefferies	Buy
Jan-28-26	Initiated	Barclays	Overweight	$231
Jan-23-26	Initiated	Roth Capital	Buy	$212
Dec-19-25	Resumed	Truist	Buy	$202
Dec-04-25	Initiated	Rothschild & Co Redburn	Buy	$263
Oct-28-25	Resumed	Cantor Fitzgerald	Overweight	$192
Oct-20-25	Initiated	Wells Fargo	Overweight	$171
Aug-20-25	Initiated	William Blair	Outperform
Aug-13-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$126
May-13-25	Initiated	Jefferies	Buy	$105
Feb-25-25	Initiated	RBC Capital Mkts	Outperform	$100
Apr-23-24	Initiated	Truist	Buy	$48
Feb-15-24	Initiated	Wolfe Research	Outperform	$42
Dec-08-23	Initiated	Wells Fargo	Overweight	$55
Nov-20-23	Resumed	JP Morgan	Overweight	$36
Jul-26-23	Initiated	Guggenheim	Buy	$50

Show Previous Ratings

Sep-21-26 07:00AM	FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027 (PR Newswire)
Sep-16-26 07:00AM	Insmed Expands Community Impact During Fifth Annual Global Day of Good (PR Newswire)
Sep-04-26 07:00AM	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Sep-03-26 07:00AM	Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026 (PR Newswire)
Aug-26-26 07:00AM	Insmed to Present at September 2026 Investor Conferences (PR Newswire)
07:00AM	Loading…
Aug-24-26 07:00AM	BRINSUPRI (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease (PR Newswire)
Aug-18-26 04:41PM	Top Analyst Reports for Visa, Lam Research & Caterpillar (Zacks)
Aug-07-26 11:39AM	What Insmed Stock's Premium Is Actually Buying (Trefis)
08:30AM	Insmed Incorporated Q2 2026 Earnings Call Summary (Moby)
Aug-06-26 03:05PM	Insmed Inc (INSM) (Q2 2026) Earnings Call Highlights: BRINSUPRI Surges 49% Sequentially, ... (GuruFocus.com) +33.86%
10:56AM	Insmed Raises BRINSUPRI Revenue Guidance After Strong Q2 Growth and Expands Peak Sales Outlook (InvestorsHub)
07:21AM	Insmed: Q2 Earnings Snapshot (Associated Press)
07:00AM	Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update (PR Newswire)
Jul-29-26 06:03AM	EMV Capital: ProAxsis eyes COPD market breakthrough with Imperial College London study (Proactive)
Jul-23-26 07:00AM	Insmed to Host Second-Quarter 2026 Financial Results Conference Call on Thursday, August 6, 2026 (PR Newswire)
06:07AM	Loading…
Jul-17-26 06:07AM	Arbutus, Sanofi escalate mRNA patent fights; InnoCares TYK2 contender advances (BioPharma Dive)
Jul-16-26 07:00AM	Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension (PR Newswire)
Jun-23-26 05:33PM	Nebius and CoreWeave fall after Nasdaq 100 listing (Blockspace)
07:00AM	Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory (PR Newswire)
Jun-22-26 12:01AM	Nasdaq-100 Onboards 5 New Stocks in AI-Fueled Rebalancing (The Daily Upside)
Jun-12-26 08:46AM	Five AI and Space Names Join the Nasdaq-100 (GuruFocus.com)
08:35AM	Nasdaq-100 Adds New AI and Space Winners. These Stocks Are Soaring (GuruFocus.com)
Jun-04-26 07:00AM	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Jun-01-26 10:08PM	ATS 2026: Insmed shines in bronchiectasis with spotlight on Brinsupri (Pharmaceutical Technology)
May-28-26 04:27PM	JPMorgan says large-cap biotech is back as profits and pipelines fuel upside (Investing.com)
May-27-26 07:00AM	Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference (PR Newswire)
May-20-26 03:29PM	JPMorgan sees biotech sector at inflection point, resumes coverage on 14 Firms (Investing.com)
May-07-26 04:58PM	Insmed Incorporated Q1 2026 Earnings Call Summary (Moby) -23.41%
07:38AM	Insmed Posts Narrower Loss In Q1 (RTT News)
07:17AM	Insmed: Q1 Earnings Snapshot (Associated Press)
07:00AM	Loading…
07:00AM	Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update (PR Newswire)
May-06-26 04:30PM	Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasis (PR Newswire)
06:30AM	Avalo shares spike on skin drug data; BioNTech to cut staff (BioPharma Dive)
May-04-26 07:00AM	Insmed to Present Data Across Its Respiratory Portfolio, Including Late-Breaking ARIKAYCE Results from Phase 3b ENCORE Study, at the American Thoracic Society International Conference 2026 (PR Newswire) +5.07%
Apr-30-26 07:00AM	Insmed to Present at May 2026 Investor Conferences (PR Newswire)
Apr-23-26 07:00AM	Insmed to Host First-Quarter 2026 Financial Results Conference Call on Thursday, May 7, 2026 (PR Newswire)
Apr-08-26 07:01AM	Insmed freezes Brinsupris HS programme on Phase II failure (Clinical Trials Arena)
05:37AM	Novo underprices Lilly with higher-dose Wegovy; Insmed absorbs expected study failure (BioPharma Dive)
Apr-07-26 04:01PM	Insmed Provides Clinical Update on Phase 2b CEDAR Study (PR Newswire)
Apr-01-26 01:05PM	Options Bulls Could Be Right About This Pharma Stock (Schaeffer's Research)
Mar-24-26 08:30AM	Insmed eyes Arikayce label expansion on Phase IIIb lung disease success (Clinical Trials Arena)
Mar-23-26 02:47PM	Nasdaq and Dow lead markets higher as Trump claims Iran peace talks (Proactive) +5.87%
11:29AM	Insmed shares rise as Arikayce trial data point to larger market opportunity (Investing.com)
10:09AM	Insmed shares rise on positive late-stage trial results for lung disease therapy (Proactive)
07:00AM	Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease (PR Newswire)
06:16AM	FDA seeks feedback on voucher program; Study data lift overhang on Insmed shares (BioPharma Dive)
Mar-06-26 12:29PM	Insmed Incorporated (INSM) Price Target Raised to $211 at BofA (Insider Monkey)
Mar-05-26 07:00AM	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Mar-01-26 01:33AM	Insmed Incorporated (INSM) Enters 2026 With Momentum (Insider Monkey)
Feb-26-26 11:53PM	Why Insmed Incorporated (INSM) is One of the Best Strong Buy Healthcare Stocks to Invest In (Insider Monkey)
Feb-24-26 07:19AM	Insmed Incorporated (INSM) Gained from Its Lead Product ARIKAYCE (Insider Monkey)
Feb-20-26 10:20AM	Insmed Lags on Q4 Earnings, Stock Gains on 2026 Brinsupri Sales View (Zacks)
09:55AM	Wall Street Analysts Think Insmed (INSM) Could Surge 33.6%: Read This Before Placing a Bet (Zacks)
03:44AM	Insmed (INSM) Poised for 2026 Upside With Potential $1.3B Arikayce Sales Boost, Roth/MKM Initiates Buy (Insider Monkey)
Feb-19-26 04:33PM	Stocks Decline Amid AI Fears and Geopolitical Risks (Barchart) +6.54%
02:03PM	Insmed Inc (INSM) Q4 2025 Earnings Call Highlights: Strong Brin Suri Launch and Promising 2026 ... (GuruFocus.com)
12:32PM	Insmed Incorporated Q4 2025 Earnings Call Summary (Moby)
09:36AM	Insmed Q4 Earnings Call Highlights (MarketBeat)
09:30AM	Insmed (INSM) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
08:10AM	Insmed (INSM) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:14AM	Insmed: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update (PR Newswire)
Feb-16-26 02:11PM	What to Expect From These Drug/Biotech Players This Earnings Season? (Zacks)
10:00AM	Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Feb-13-26 07:00AM	Insmed To Present at March 2026 Investor Conferences (PR Newswire)
Feb-12-26 10:00AM	Insmed (INSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Feb-05-26 07:00AM	Insmed to Host Fourth-Quarter and Full-Year 2025 Financial Results Conference Call on Thursday, February 19, 2026 (PR Newswire)
Feb-02-26 01:30AM	The Druckenmiller Connection: Meet the Man Behind Bessent and Warsh (Barrons.com)
Jan-28-26 07:00AM	Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 Congress (PR Newswire)
Jan-23-26 07:50AM	Here Are Fridays Top Wall Street Analyst Research Calls: Applied Materials, e.l.f. Beauty, Fortinet, Freeport MacMoRan, Procter & Gamble, Spotify, and More (24/7 Wall St.)
Jan-19-26 01:04AM	Analyst Weighs Patent Cliff Risks Against Insmed's (INSM) Growth Story (Insider Monkey)
Jan-12-26 07:08PM	Insmed CEO Will Lewis talks its rare disease drug pipeline (CNBC TV)
09:32AM	INSM Stock Jumps on 2025 Preliminary Sales, 2026 Goals Announced (Zacks)
Jan-09-26 04:38PM	S&P 500 Rallies to a New Record High on US Economic Optimism (Barchart)
11:19AM	Healthcare dealmakers head to San Francisco hoping for megamergers in 2026 (Reuters)
10:58AM	Insmed Maps Aggressive 2026 As Newly Approved Lung Disease Drug Gains Traction, Pipeline Advances (Benzinga)
09:44AM	Stock Market Today: Dow Up After Surprise Jobs Data; Trump Tariff Ruling Looms (Live Coverage) (Investor's Business Daily)
07:00AM	Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
06:28AM	Insmeds ginormous lung drug sales; J&Js US pricing deal (BioPharma Dive)
Jan-08-26 07:20AM	Jim Cramer on Insmed: "This One Is Worth Keeping an Eye On" (Insider Monkey)
Jan-05-26 10:19AM	Stock Market Today: Dow Jumps After U.S. Ousts Maduro; Energy Shines, Nvidia Rallies Ahead (Live Coverage) (Investor's Business Daily)
09:01AM	Bet on These 3 Small-Cap ETFs to Ride the January Effect (Zacks)
Jan-02-26 08:15AM	INSM Stock Up 78% in 6 Months: Here's What You Need to Know (Zacks)
07:00AM	Insmed To Present at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-31-25 09:01AM	Ultragenyx (RARE) Moves 15.5% Higher: Will This Strength Last? (Zacks)
Dec-30-25 04:31PM	Stocks Fall Slightly in Thin Holiday Trade (Barchart)
11:06AM	Stocks Slip as Bond Yields Rise (Barchart)
Dec-26-25 02:33AM	The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar (Zacks)
Dec-24-25 10:51AM	4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow (Zacks)
Dec-18-25 06:15PM	Mizuho's Jared Holz talks Insmed sinking double digits on sinus drug trial news (CNBC TV) -16.08%
04:33PM	Stocks Settle Higher on Upbeat Tech Outlook and Cooling Inflation (Barchart)
04:15PM	The 'Worst-Case Scenario' Why Insmed Just Reversed After A 181% Six-Month Sprint (Investor's Business Daily)
04:13PM	These Stocks Moved the Most Today: Micron, DJT, Accenture, Tilray, Lululemon, Medline, Rivian, and More (Barrons.com)
03:13PM	These Stocks Are Moving the Most Today: Micron, DJT, Accenture, Tilray, Lululemon, Medline, Rivian, and More (Barrons.com)
07:59AM	INSM Stock Plummets on Sinus Study Failure, Adds New Pipeline Asset (Zacks)
07:12AM	Insmed Stock Plummets 19%. This Is What Sparked the Selloff. (Barrons.com)
06:10AM	These Stocks Are Moving the Most Today: Micron, Sandisk, Lululemon, Insmed, Rivian, PayPal, and More (Barrons.com)
06:02AM	Insmeds win streak ends as top drug fails study in chronic nasal condition (BioPharma Dive)
Dec-17-25 04:01PM	Insmed Provides Clinical and Business Update (PR Newswire)
Dec-15-25 12:15PM	MicroStrategy retains place in key index despite delisting threats (TheStreet)

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

M.B.A.Mr. William H. Lewis J.D.

Chief Financial OfficerMs. Sara M. Bonstein M.B.A.

Chief Operating OfficerMr. Roger Adsett M.B.A.

Chief Legal Officer & Corporate SecretaryMr. Michael Alexander Smith J.D.

M.D.Dr. Martina Flammer M.B.A.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Brennan David R	Director	Sep 09 '26	Sale	124.00	25,000	3,100,000	39,238	Sep 11 04:04 PM
Brennan David R	Director	Sep 09 '26	Proposed Sale	123.99	25,000	3,099,729		Sep 10 10:22 AM
SHAROKY MELVIN MD	Director	Aug 17 '26	Sale	127.53	5,000	637,650	0	Aug 19 04:10 PM
MELVIN SHAROKY	Director	Aug 17 '26	Proposed Sale	127.53	5,000	637,637		Aug 17 04:18 PM
Adsett Roger	Chief Operating Officer	Aug 10 '26	Option Exercise	20.45	239,850	4,905,570	338,594	Aug 12 05:04 PM
Adsett Roger	Chief Operating Officer	Aug 10 '26	Sale	133.27	239,850	31,964,810	98,744	Aug 12 05:04 PM
Roger Adsett	Officer	Aug 10 '26	Proposed Sale	133.26	239,850	31,963,198		Aug 10 05:42 PM
Flammer Martina M.D.	Chief Medical Officer	Aug 06 '26	Option Exercise	21.20	27,173	576,126	87,659	Aug 07 04:39 PM
Flammer Martina M.D.	Chief Medical Officer	Aug 06 '26	Sale	128.61	27,173	3,494,838	60,486	Aug 07 04:39 PM
Martina Flammer	Officer	Aug 06 '26	Proposed Sale	128.61	27,173	3,494,755		Aug 06 04:09 PM
Lewis William	Chair and CEO	Jul 23 '26	Option Exercise	24.94	10,700	266,870	269,758	Jul 24 05:02 PM
Lewis William	Chair and CEO	Jul 23 '26	Sale	106.06	10,700	1,134,890	259,058	Jul 24 05:02 PM
William Lewis	Officer	Jul 23 '26	Proposed Sale	106.06	10,700	1,134,867		Jul 23 04:38 PM
Lewis William	Chair and CEO	Jul 09 '26	Option Exercise	24.94	10,699	266,840	269,757	Jul 10 04:02 PM
Lewis William	Chair and CEO	Jul 09 '26	Sale	117.40	10,699	1,256,084	259,058	Jul 10 04:02 PM
William Lewis	Officer	Jul 09 '26	Proposed Sale	117.40	10,699	1,256,029		Jul 09 04:29 PM
Flammer Martina M.D.	Chief Medical Officer	Jul 06 '26	Option Exercise	25.80	12,302	317,445	72,788	Jul 08 04:03 PM
Flammer Martina M.D.	Chief Medical Officer	Jul 06 '26	Sale	109.98	12,302	1,352,932	60,486	Jul 08 04:03 PM
Martina Flammer	Officer	Jul 06 '26	Proposed Sale	109.97	12,302	1,352,864		Jul 06 04:20 PM
Lewis William	Chair and CEO	Jun 25 '26	Option Exercise	24.94	21,398	533,679	280,315	Jun 26 04:03 PM
Lewis William	Chair and CEO	Jun 25 '26	Sale	103.32	21,398	2,210,763	258,917	Jun 26 04:03 PM
William Lewis	Officer	Jun 25 '26	Proposed Sale	103.31	21,398	2,210,653		Jun 25 04:14 PM
Smith Michael Alexander	Chief Legal Officer	Jun 22 '26	Sale	95.82	1,806	173,051	37,648	Jun 24 04:11 PM
Michael Smith	Officer	Jun 22 '26	Proposed Sale	95.81	1,806	173,039		Jun 22 04:20 PM
Lewis William	Chair and CEO	Jun 08 '26	Sale	94.03	6,515	612,605	258,917	Jun 10 04:05 PM
William Lewis	Officer	Jun 08 '26	Proposed Sale	94.03	6,515	612,576		Jun 08 04:34 PM
Martina Flammer	Officer	Jun 05 '26	Proposed Sale	103.77	1,858	192,811		Jun 05 04:18 PM
Adsett Roger	Chief Operating Officer	Jun 03 '26	Sale	102.27	2,370	242,380	98,603	Jun 05 04:15 PM
Bonstein Sara	Chief Financial Officer	Jun 03 '26	Sale	102.27	2,404	245,857	69,082	Jun 05 04:14 PM
Smith Michael Alexander	Chief Legal Officer	Jun 03 '26	Sale	102.27	2,159	220,801	39,454	Jun 05 04:14 PM
Lewis William	Chair and CEO	Jun 03 '26	Sale	102.27	7,605	777,763	265,432	Jun 05 04:12 PM
Flammer Martina M.D.	Chief Medical Officer	Jun 03 '26	Sale	102.27	2,566	262,425	62,344	Jun 05 04:11 PM
Flammer Martina M.D.	Chief Medical Officer	Jun 05 '26	Sale	103.78	1,858	192,823	60,486	Jun 05 04:11 PM
Sara Bonstein	Officer	Jun 03 '26	Proposed Sale	102.27	2,404	245,857		Jun 03 04:41 PM
Martina Flammer	Officer	Jun 03 '26	Proposed Sale	102.27	2,566	262,424		Jun 03 04:35 PM
Roger Adsett	Officer	Jun 03 '26	Proposed Sale	102.27	2,370	242,379		Jun 03 04:28 PM
Michael Smith	Officer	Jun 03 '26	Proposed Sale	102.27	2,159	220,800		Jun 03 04:21 PM
William Lewis	Officer	Jun 03 '26	Proposed Sale	102.27	7,605	777,763		Jun 03 04:10 PM
Michael Smith	Officer	May 22 '26	Proposed Sale	108.46	6,149	666,951		May 22 04:55 PM
Smith Michael Alexander	Chief Legal Officer	May 22 '26	Sale	108.47	6,149	666,982	41,613	May 22 04:25 PM
Lewis William	Chair and CEO	May 18 '26	Option Exercise	24.94	10,699	266,840	298,601	May 20 04:06 PM
Lewis William	Chair and CEO	May 18 '26	Sale	106.33	25,564	2,718,224	273,037	May 20 04:06 PM
William Lewis	Officer	May 18 '26	Proposed Sale	106.33	25,564	2,718,106		May 18 04:53 PM
Bonstein Sara	Chief Financial Officer	May 13 '26	Sale	116.18	8,272	961,041	71,486	May 15 04:08 PM
Adsett Roger	Chief Operating Officer	May 13 '26	Sale	116.18	5,837	678,143	100,973	May 15 04:07 PM
Flammer Martina M.D.	Chief Medical Officer	May 14 '26	Sale	117.54	10,479	1,231,702	64,910	May 15 04:07 PM
Flammer Martina M.D.	Chief Medical Officer	May 13 '26	Sale	114.23	7,854	897,190	75,389	May 15 04:07 PM
Smith Michael Alexander	Chief Legal Officer	May 13 '26	Sale	116.18	4,109	477,384	47,762	May 15 04:07 PM
Lewis William	Chair and CEO	May 13 '26	Sale	116.18	13,283	1,543,219	287,902	May 15 04:06 PM
Martina Flammer	Officer	May 14 '26	Proposed Sale	117.53	10,479	1,231,599		May 14 05:20 PM
Roger Adsett	Officer	May 13 '26	Proposed Sale	116.18	5,837	678,142		May 13 05:24 PM
Michael Smith	Officer	May 13 '26	Proposed Sale	116.18	4,109	477,383		May 13 05:18 PM
Sara Bonstein	Officer	May 13 '26	Proposed Sale	116.18	8,272	961,040		May 13 05:17 PM
Martina Flammer	Officer	May 13 '26	Proposed Sale	114.23	7,854	897,145		May 13 05:17 PM
William Lewis	Officer	May 13 '26	Proposed Sale	116.18	13,283	1,543,218		May 13 05:14 PM
Flammer Martina M.D.	Chief Medical Officer	May 11 '26	Option Exercise	17.07	12,949	221,039	96,192	May 13 04:50 PM
Flammer Martina M.D.	Chief Medical Officer	May 11 '26	Sale	100.40	12,949	1,300,121	83,243	May 13 04:50 PM
Martina Flammer	Officer	May 11 '26	Proposed Sale	100.40	12,949	1,300,105		May 11 04:46 PM
Lewis William	Chair and CEO	May 04 '26	Option Exercise	24.94	10,699	266,840	311,884	May 06 04:11 PM
Lewis William	Chair and CEO	May 04 '26	Sale	137.34	10,699	1,469,442	301,185	May 06 04:11 PM
William Lewis	Officer	May 04 '26	Proposed Sale	137.35	10,699	1,469,481		May 04 04:55 PM
Lewis William	Chair and CEO	Apr 16 '26	Option Exercise	24.94	10,699	266,840	311,884	Apr 17 04:43 PM
Lewis William	Chair and CEO	Apr 16 '26	Sale	143.97	10,699	1,540,332	301,185	Apr 17 04:43 PM
William Lewis	Officer	Apr 16 '26	Proposed Sale	143.97	10,699	1,540,292		Apr 16 04:17 PM
Lewis William	Chair and CEO	Apr 06 '26	Option Exercise	24.94	10,699	266,840	311,884	Apr 08 04:41 PM
Lewis William	Chair and CEO	Apr 06 '26	Sale	163.22	10,699	1,746,336	301,185	Apr 08 04:41 PM
William Lewis	Officer	Apr 06 '26	Proposed Sale	163.22	10,699	1,746,319		Apr 06 04:42 PM
Adsett Roger	Chief Operating Officer	Apr 01 '26	Option Exercise	14.56	88,060	1,282,154	194,870	Apr 03 04:07 PM
Adsett Roger	Chief Operating Officer	Apr 01 '26	Sale	164.63	88,060	14,497,651	106,810	Apr 03 04:07 PM
Roger Adsett	Officer	Apr 01 '26	Proposed Sale	164.27	88,060	14,465,616		Apr 01 05:10 PM
Smith Michael Alexander	Chief Legal Officer	Mar 30 '26	Option Exercise	24.78	19,638	486,582	71,509	Mar 31 04:13 PM
Smith Michael Alexander	Chief Legal Officer	Mar 30 '26	Sale	150.98	19,638	2,964,945	51,871	Mar 31 04:13 PM
Michael Smith	Officer	Mar 30 '26	Proposed Sale	150.98	19,638	2,964,929		Mar 30 05:31 PM
Lewis William	Chair and CEO	Mar 19 '26	Option Exercise	24.94	10,699	266,840	311,884	Mar 20 04:05 PM
Lewis William	Chair and CEO	Mar 19 '26	Sale	143.52	10,699	1,535,542	301,185	Mar 20 04:05 PM
William Lewis	Officer	Mar 19 '26	Proposed Sale	143.52	10,699	1,535,514		Mar 19 04:57 PM
William Lewis	Officer	Mar 05 '26	Proposed Sale	146.02	10,699	1,562,311		Mar 05 04:59 PM
Lewis William	Chair and CEO	Mar 05 '26	Option Exercise	24.94	10,699	266,840	311,884	Mar 05 04:16 PM
Lewis William	Chair and CEO	Mar 05 '26	Sale	146.03	10,699	1,562,328	301,185	Mar 05 04:16 PM
Smith Michael Alexander	Chief Legal Officer	Feb 24 '26	Option Exercise	17.07	20,248	345,633	76,645	Feb 25 04:04 PM
Smith Michael Alexander	Chief Legal Officer	Feb 24 '26	Sale	155.77	24,774	3,859,157	51,871	Feb 25 04:04 PM
Michael Smith	Officer	Feb 24 '26	Proposed Sale	155.77	24,774	3,859,153		Feb 24 04:33 PM
Lewis William	Chair and CEO	Feb 19 '26	Option Exercise	24.94	10,699	266,840	311,884	Feb 23 04:34 PM
Lewis William	Chair and CEO	Feb 19 '26	Sale	150.97	10,699	1,615,257	301,185	Feb 23 04:34 PM
William Lewis	Officer	Feb 19 '26	Proposed Sale	150.97	10,699	1,615,250		Feb 19 04:54 PM
Lewis William	Chair and CEO	Feb 09 '26	Option Exercise	24.94	10,699	266,840	314,581	Feb 11 04:42 PM
Lewis William	Chair and CEO	Feb 09 '26	Sale	147.79	13,396	1,979,764	301,185	Feb 11 04:42 PM
William Lewis	Officer	Feb 09 '26	Proposed Sale	147.79	13,396	1,979,774		Feb 09 05:32 PM
Flammer Martina M.D.	Chief Medical Officer	Feb 05 '26	Sale	152.44	869	132,470	83,243	Feb 06 04:18 PM
Martina Flammer	Officer	Feb 05 '26	Proposed Sale	152.43	869	132,462		Feb 05 05:12 PM
Adsett Roger	Chief Operating Officer	Feb 03 '26	Sale	156.17	791	123,530	106,810	Feb 04 04:20 PM
Bonstein Sara	Chief Financial Officer	Feb 03 '26	Sale	156.34	748	116,942	79,758	Feb 04 04:19 PM
Lewis William	Chair and CEO	Feb 03 '26	Sale	156.34	3,009	470,427	303,882	Feb 04 04:17 PM
Smith Michael Alexander	Chief Legal Officer	Feb 03 '26	Sale	156.27	640	100,013	56,397	Feb 04 04:15 PM
Flammer Martina M.D.	Chief Medical Officer	Feb 02 '26	Option Exercise	65.72	7,982	524,577	92,889	Feb 04 04:15 PM
Flammer Martina M.D.	Chief Medical Officer	Feb 02 '26	Sale	154.59	7,982	1,233,959	84,907	Feb 04 04:15 PM
Flammer Martina M.D.	Chief Medical Officer	Feb 03 '26	Sale	155.77	795	123,837	84,112	Feb 04 04:15 PM
Roger Adsett	Officer	Feb 03 '26	Proposed Sale	156.16	791	123,526		Feb 03 05:04 PM
Michael Smith	Officer	Feb 03 '26	Proposed Sale	156.27	640	100,012		Feb 03 05:02 PM
William Lewis	Officer	Feb 03 '26	Proposed Sale	156.33	3,009	470,412		Feb 03 04:58 PM

RVMD

Revolution Medicines Inc

INSM

Insmed Inc

Upgrade your Finviz experience